National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 8) (No. PB 57 of 2013) (Cth)

PB 57 of 2013

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 8)

National Health Act 1953

___________________________________________________________________________

I, Steve Dunlop, Acting Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Medical Research, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated 19 August 2013

STEVE DUNLOP

Acting Assistant Secretary

Pharmaceutical Access Branch

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

1              Name of Instrument

(1)This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No.8).

(2)This Instrument may also be cited as PB 57 of 2013.

2             Commencement

This Instrument commences on 1 September 2013.

3              Amendments to PB 79 of 2011

Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

Schedule 1                   Amendments

1. Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride) with manner of administration Injection:

omit:

Gemzar LY MP D

1. Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride) with manner of administration Injection:

omit:

Gemzar LY MP D

1. Schedule 1 Part 1, after entry for Gemcitabine in the form Powder for I.V. infusion 2 g  (as hydrochloride) with manner of administration Injection with a brand of DBL Gemcitabine for Injection:

insert:

Gemcitabine Actavis
2000 WQ MP D

1. Schedule 1 Part 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 100 mg in 16.7 mL with manner of administration Injection:

omit:

Paclitaxel Pfizer PF MP C3186
C3890 
C3902
C3917
C3955
C3956 D

1. Schedule 1 Part 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 30 mg in 5 mL with manner of administration Injection:

omit:

Paclitaxel Pfizer PF MP C3186
C3890 
C3902
C3917
C3955
C3956 D

1. Schedule 2, entry for Granisetron in the form Concentrated injection 3 mg (as hydrochloride) in 3 mL with manner of administration Injection with a brand of Granisetron Kabi:

substitute:  

Concentrated injection 3 mg (as hydrochloride) in 3 mL Injection Granisteron-AFT Granisetron Kabi AE PK EMP EMP C4139 C4139

1 1

0


0

1. Schedule 2, entry for Ondansetron in the form I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL with manner of administration Injection:

omit:

Zofran AS EMP C3050 1 0

1. Schedule 2, entry for Ondansetron in the form I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL with manner of administration Injection:

omit:

Zofran AS EMP C3050 1 0